In the absence of evidence for the effectiveness of treating Covid-19, this trial is looking at the effectiveness of three new drugs which have been used to treat other conditions. This is an adaptive study, which means that the results will be closely monitored to see if there are some treatment arms which are more effective than others: if this is the case, the treatment arm will be stopped.
This is a study which is considered a national priority.
Participants will be randomised into one of four treatment arms
- No additional treatment (ie standard care)
- Lopinavir-Ritonavir: a drug combination used to treat HIV
- Azithromycin, an antibiotic used to treat bacterial infections
- Low dose corticosteroids
Who can participate?
Patients will be eligible if they are:
- Aged at least 18 years
- Confirmation of SARS-CoV-2 infection by PCR
- No medical history that might, in the opinion of the attending clinician, put the patient at significant risk if he/she were to participate in the trial. The R&I Team have expertise to be able to guide on this.